BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38457494)

  • 1. ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia.
    Behrens K; Brajanovski N; Xu Z; Viney EM; DiRago L; Hediyeh-Zadeh S; Davis MJ; Pearson RB; Sanij E; Alexander WS; Ng AP
    Sci Adv; 2024 Mar; 10(10):eadj8803. PubMed ID: 38457494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γ-Catenin-Dependent Signals Maintain BCR-ABL1
    Luong-Gardiol N; Siddiqui I; Pizzitola I; Jeevan-Raj B; Charmoy M; Huang Y; Irmisch A; Curtet S; Angelov GS; Danilo M; Juilland M; Bornhauser B; Thome M; Hantschel O; Chalandon Y; Cazzaniga G; Bourquin JP; Huelsken J; Held W
    Cancer Cell; 2019 Apr; 35(4):649-663.e10. PubMed ID: 30991025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.
    McClellan JS; Dove C; Gentles AJ; Ryan CE; Majeti R
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):4074-9. PubMed ID: 25775523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
    Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
    Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
    Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
    Steeghs EMP; Bakker M; Hoogkamer AQ; Boer JM; Hartman QJ; Stalpers F; Escherich G; de Haas V; de Groot-Kruseman HA; Pieters R; den Boer ML
    Sci Rep; 2018 Jan; 8(1):693. PubMed ID: 29330417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
    Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
    Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
    Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
    Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia.
    Peterson JF; Ketterling RP; Huang L; Finn LE; Shi M; Hoppman NL; Greipp PT; Baughn LB
    Genes Chromosomes Cancer; 2019 Sep; 58(9):665-668. PubMed ID: 30790375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
    Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
    Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BCL-2 as a Therapeutic Strategy for Primary
    Massimino M; Tirrò E; Stella S; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Romeo MA; DI Raimondo F; Manzella L
    In Vivo; 2020; 34(2):511-516. PubMed ID: 32111748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile.
    Messina M; Chiaretti S; Iacobucci I; Tavolaro S; Lonetti A; Santangelo S; Elia L; Papayannidis C; Paoloni F; Vitale A; Guarini A; Martinelli G; Foà R
    Br J Haematol; 2011 Mar; 152(6):727-32. PubMed ID: 21623761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucin 4 protein is expressed in B-acute lymphoblastic leukemia and is restricted to BCR::ABL1-positive and BCR::ABL-like subtypes.
    Gestrich CK; De Lancy SJ; Kresak A; Sinno MG; Yalley A; Pateva I; Meyerson H; Shetty S; Oduro KA
    Hum Pathol; 2023 Jun; 136():75-83. PubMed ID: 37023866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
    Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
    Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
    Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
    Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia.
    Hajingabo LJ; Daakour S; Martin M; Grausenburger R; Panzer-Grümayer R; Dequiedt F; Simonis N; Twizere JC
    Mol Biol Cell; 2014 Dec; 25(24):3973-85. PubMed ID: 25273558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
    Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
    J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.